+

WO1998010762A3 - Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride - Google Patents

Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride Download PDF

Info

Publication number
WO1998010762A3
WO1998010762A3 PCT/GB1997/002418 GB9702418W WO9810762A3 WO 1998010762 A3 WO1998010762 A3 WO 1998010762A3 GB 9702418 W GB9702418 W GB 9702418W WO 9810762 A3 WO9810762 A3 WO 9810762A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
controlled release
methoxyimino
dosage form
release dosage
Prior art date
Application number
PCT/GB1997/002418
Other languages
French (fr)
Other versions
WO1998010762A2 (en
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ334268A priority Critical patent/NZ334268A/en
Priority to BR9711734A priority patent/BR9711734A/en
Priority to JP10513352A priority patent/JP2001500150A/en
Priority to CZ99832A priority patent/CZ83299A3/en
Priority to PL97332074A priority patent/PL332074A1/en
Priority to EP97939064A priority patent/EP0929301A2/en
Priority to HU9904401A priority patent/HUP9904401A3/en
Priority to AU41288/97A priority patent/AU724086B2/en
Priority to IL12878197A priority patent/IL128781A0/en
Priority to CA002265661A priority patent/CA2265661A1/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp, Susan Marie Milosovich, William Muldoon, James Albert Napper, Laurence Rousseau, Joseph Sauer filed Critical Smithkline Beecham Plc
Publication of WO1998010762A2 publication Critical patent/WO1998010762A2/en
Publication of WO1998010762A3 publication Critical patent/WO1998010762A3/en
Priority to NO991194A priority patent/NO991194D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A controlled release formulation of an acetonitrile compound and its use in the treatment and/or prophylaxis of certain disorders.
PCT/GB1997/002418 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride WO1998010762A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL12878197A IL128781A0 (en) 1996-09-12 1997-09-08 Controlled release dosage form of (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride
JP10513352A JP2001500150A (en) 1996-09-12 1997-09-08 Controlled release dosage form of [R- (Z)]-α- (methoxyimino) -α- (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile monohydrochloride
CZ99832A CZ83299A3 (en) 1996-09-12 1997-09-08 Dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyklo[2,2,2]okt-3-yl)acetonitrile monohydrochloride with controlled release
PL97332074A PL332074A1 (en) 1996-09-12 1997-09-08 Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride
EP97939064A EP0929301A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2]oct-3-yl)acetonitrile monohydrochloride
NZ334268A NZ334268A (en) 1996-09-12 1997-09-08 Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride
AU41288/97A AU724086B2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride
HU9904401A HUP9904401A3 (en) 1996-09-12 1997-09-08 Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride
CA002265661A CA2265661A1 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl)acetonitrile monohydrochloride
BR9711734A BR9711734A (en) 1996-09-12 1997-09-08 Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride
NO991194A NO991194D0 (en) 1996-09-12 1999-03-11 Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9619074.9 1996-09-12
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09254621 A-371-Of-International 1999-03-11
US09/759,576 Continuation US20010003588A1 (en) 1996-09-12 2001-01-12 Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride

Publications (2)

Publication Number Publication Date
WO1998010762A2 WO1998010762A2 (en) 1998-03-19
WO1998010762A3 true WO1998010762A3 (en) 1998-06-04

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Country Status (22)

Country Link
EP (1) EP0929301A2 (en)
JP (1) JP2001500150A (en)
KR (1) KR20000036039A (en)
CN (2) CN1235544A (en)
AR (1) AR008176A1 (en)
AU (1) AU724086B2 (en)
BR (1) BR9711734A (en)
CA (1) CA2265661A1 (en)
CO (1) CO5031291A1 (en)
CZ (1) CZ83299A3 (en)
GB (1) GB9619074D0 (en)
HU (1) HUP9904401A3 (en)
ID (1) ID19589A (en)
IL (1) IL128781A0 (en)
MA (1) MA24359A1 (en)
NO (1) NO991194D0 (en)
NZ (1) NZ334268A (en)
PE (1) PE2499A1 (en)
PL (1) PL332074A1 (en)
TR (1) TR199900505T2 (en)
WO (1) WO1998010762A2 (en)
ZA (1) ZA978133B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (en) * 1998-03-04 2001-04-20 Gattefosse Ets Sa ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE
EP1061918A1 (en) * 1998-03-11 2000-12-27 Smithkline Beecham Plc Controlled release composition of (1-azabicyclo(2.2.2)oct-3-yl)acetonitrile monohydrochloride
DE19918325A1 (en) * 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
FR2796840B1 (en) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques LOW-DOSE TABLETS AND METHOD OF PREPARATION
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
PE20040134A1 (en) 2002-07-25 2004-03-06 Pharmacia Corp PRAMIPEXOL ONCE-A-DAY DOSAGE FORM
JP4808612B2 (en) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 Composition for oral administration containing alkylenedioxybenzene derivative
ES2273271T5 (en) * 2003-05-14 2013-05-21 Aptalis Pharma Limited Composition of controlled release of mechanical stress resistant drug in vivo
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (en) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk Method for producing solid preparation
MX2007001765A (en) 2004-08-13 2007-04-20 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof.
AU2005271193B2 (en) * 2004-08-13 2011-11-24 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392803A1 (en) * 1989-04-13 1990-10-17 Beecham Group p.l.c. Novel compounds
WO1995031457A1 (en) * 1994-05-14 1995-11-23 Smithkline Beecham Plc Derivatives of quinuclidine n-oxide as muscarinic receptor ligands
WO1996012486A1 (en) * 1994-10-25 1996-05-02 Smithkline Beecham P.L.C. Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease
WO1997004750A2 (en) * 1995-07-29 1997-02-13 Smithkline Beecham Plc Process for preparing solid dosage forms of very low-dose drugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392803A1 (en) * 1989-04-13 1990-10-17 Beecham Group p.l.c. Novel compounds
WO1995031457A1 (en) * 1994-05-14 1995-11-23 Smithkline Beecham Plc Derivatives of quinuclidine n-oxide as muscarinic receptor ligands
WO1996012486A1 (en) * 1994-10-25 1996-05-02 Smithkline Beecham P.L.C. Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease
WO1997004750A2 (en) * 1995-07-29 1997-02-13 Smithkline Beecham Plc Process for preparing solid dosage forms of very low-dose drugs

Also Published As

Publication number Publication date
ZA978133B (en) 1999-04-12
NO991194L (en) 1999-03-11
WO1998010762A2 (en) 1998-03-19
MA24359A1 (en) 1998-07-01
PL332074A1 (en) 1999-08-30
CN1446535A (en) 2003-10-08
AU4128897A (en) 1998-04-02
HUP9904401A2 (en) 2000-06-28
IL128781A0 (en) 2000-01-31
AU724086B2 (en) 2000-09-14
JP2001500150A (en) 2001-01-09
PE2499A1 (en) 1999-03-24
TR199900505T2 (en) 1999-06-21
BR9711734A (en) 1999-08-24
NO991194D0 (en) 1999-03-11
GB9619074D0 (en) 1996-10-23
AR008176A1 (en) 1999-12-09
CO5031291A1 (en) 2001-04-27
EP0929301A2 (en) 1999-07-21
CA2265661A1 (en) 1998-03-19
ID19589A (en) 1998-07-23
CZ83299A3 (en) 1999-08-11
HUP9904401A3 (en) 2001-03-28
CN1235544A (en) 1999-11-17
NZ334268A (en) 2000-10-27
KR20000036039A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
AU4217499A (en) Composition having therapeutic and/or nutritionally active substituent
AU4651693A (en) Methods and devices for relaxing smooth muscle contractions
NO308854B1 (en) Therapeutic Compounds, Pharmaceutically Acceptable Salts and Formulations Containing the Compounds, and Uses thereof
EP0630613A3 (en) Orthopedic fastener applicator.
AU6396598A (en) Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
EP1067130A4 (en) Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient
WO1998010762A3 (en) Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride
AU5852794A (en) Sterilization devices, sporidical compositions, sterilization methods, and devices for reducing surface tension
AU3780393A (en) Quinobenzoxazine, quinobenzothiazine, and pyrido-acridine antineoplastic agents
AU6410494A (en) Device for the transdermal administration of alprazolam
EP1017980A4 (en) Methods of the identification of pharmaceutically active compounds
EP0960885A4 (en) Depsipeptides and drugs containing the same as the active ingredient
AU2807492A (en) Use of misoprostol for the treatment of allergy
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
HUT69064A (en) Colloidal dispersible active ingredient compositions
ZA941199B (en) Physiologically active compound HS-1 and process for the preparation of the same
EP0938898A3 (en) Treatment of pruritus
AU3695297A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
ZA942959B (en) Controlled release formulation.
EP0852503A4 (en) Composition for the treatment of diarrhea, its use and its preparation
AU662651B2 (en) Sulfamoyltriazole derivative and bactericide containing the same as active ingredient
AU4585993A (en) Use of angiotensin ii antagonists for the treatment of hyperlipidaeme
AU3070192A (en) Uses of 1,1,1,3,3,3-hexafluoropropane
ZA977957B (en) Pharmacologically active compounds and use.
AU4136897A (en) 2,3-dihydrobenzofuran derivative and hepatopathy remedy comprising the same as active ingredient

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199411.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 334268

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1997939064

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1999/00505

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PV1999-832

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2265661

Country of ref document: CA

Ref document number: 2265661

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/002404

Country of ref document: MX

Ref document number: 1019997002030

Country of ref document: KR

Ref document number: 09254621

Country of ref document: US

ENP Entry into the national phase

Ref document number: 1998 513352

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997939064

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-832

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997002030

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997939064

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997002030

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-832

Country of ref document: CZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载